| Pharmaceutical Intermediates and APIs | Manufacture and sale of fermentation-based intermediates and Active Pharmaceutical Ingredients focused on anti-tuberculosis and antibiotic drugs. | Proprietary fermentation process technology; longstanding industry experience; strategic location; forward integration into API production. | B2B pharmaceutical companies both in India and globally, especially in US and Europe. | Fermentation-based intermediates and newly commissioned synthetic API products. | 150 | 100 | Product sales to pharmaceutical manufacturers in domestic and export markets. | Direct sales with contractual supply agreements, mostly recurring revenue model. | Expansion of fermentation and API production capacity; increasing global demand for tuberculosis-related drugs; R&D for new products. | Rifamycin S, Rifamycin O |
